{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:35:15Z","timestamp":1791286515816,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[1996,7,1]],"date-time":"1996-07-01T00:00:00Z","timestamp":836179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[1996,7]]},"DOI":"10.1038\/nm0796-760","type":"journal-article","created":{"date-parts":[[2004,8,19]],"date-time":"2004-08-19T01:39:00Z","timestamp":1092879540000},"page":"760-766","source":"Crossref","is-referenced-by-count":613,"title":["Ordered accumulation of mutations in HIV protease confers resistance to ritonavir"],"prefix":"10.1038","volume":"2","author":[{"given":"Akhteruzzaman","family":"Molla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Korneyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudthida","family":"Vasavanonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaline J.","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Chernyavskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Richard","family":"Granneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.B.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Norbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale J.","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[1996,7,1]]},"reference":[{"key":"BFnm0796760_CR1","doi-asserted-by":"publisher","first-page":"S507","DOI":"10.1093\/clinids\/12.Supplement_5.S507","volume":"12","author":"DD Richman","year":"1990","unstructured":"Richman, D.D. Zidovudine resistance of human immunodeficiency virus. Rev. Infect. Dis. 12, S507\u2013S512 (1990).","journal-title":"Rev. Infect. Dis."},{"key":"BFnm0796760_CR2","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","volume":"92","author":"D Kempf","year":"1995","unstructured":"Kempf, D. et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92, 2484\u20132488 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0796760_CR3","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1056\/NEJM199512073332303","volume":"333","author":"SA Danner","year":"1995","unstructured":"Danner, S.A. et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333, 1528\u20131533 (1995).","journal-title":"N. Engl. J. Med."},{"key":"BFnm0796760_CR4","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1056\/NEJM199512073332204","volume":"333","author":"M Markowitz","year":"1995","unstructured":"Markowitz, M. et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333, 1534\u20131539 (1995).","journal-title":"N. Engl. J. Med."},{"key":"BFnm0796760_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/373123a0","volume":"373","author":"DD Ho","year":"1995","unstructured":"Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123\u2013126 (1995).","journal-title":"Nature"},{"key":"BFnm0796760_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/373117a0","volume":"373","author":"X Wei","year":"1995","unstructured":"Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117\u2013122 (1995).","journal-title":"Nature"},{"key":"BFnm0796760_CR7","volume-title":"Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir","author":"B Cameron","year":"1996","unstructured":"Cameron, B. et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan. 28\u2013Feb. 1, 1996, Abstract LB6a."},{"key":"BFnm0796760_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/374569a0","volume":"374","author":"JH Condra","year":"1995","unstructured":"Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569\u2013571 (1995).","journal-title":"Nature"},{"key":"BFnm0796760_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/00042560-199504120-00003","volume":"8","author":"C Pachl","year":"1995","unstructured":"Pachl, C. et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. Acquir. Immune Defic. Syndr. Hum. Retroviral. 8, 446\u2013454 (1995).","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retroviral."},{"key":"BFnm0796760_CR10","volume-title":"Human Retroviruses and AIDS","author":"G Myers","year":"1993","unstructured":"Myers, G., Wain-Hobson, S., Korber, B., Smith, R.F. & Pavlakis, G.N. Human Retroviruses and AIDS (Los Alamos National Laboratory, Los Alamos, New Mexico, 1993)."},{"key":"BFnm0796760_CR11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1128\/JVI.69.2.701-706.1995","volume":"69","author":"M Markowitz","year":"1995","unstructured":"Markowitz, M. et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69, 701 (1995).","journal-title":"J. Virol."},{"key":"BFnm0796760_CR12","first-page":"S169","volume":"11","author":"H Jacobsen","year":"1995","unstructured":"Jacobsen, H. et al. In-vivo resistance to HIV proteinase inhibitor saquinavir\u2014an update. AIDS Res. Hum. Retrovir. 11, S169\u2013S169 (1995).","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"BFnm0796760_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0166-0934(88)90134-6","volume":"20","author":"R Pauwels","year":"1988","unstructured":"Pauwels, R. et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20, 309\u2013321 (1988).","journal-title":"J. Virol. Methods"},{"key":"BFnm0796760_CR14","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1128\/JVI.69.9.5228-5235.1995","volume":"69","author":"JA Partaledis","year":"1995","unstructured":"Partaledis, J.A. et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethy-lamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69, 5228\u20135235 (1995).","journal-title":"J. Virol."},{"key":"BFnm0796760_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1128\/AAC.40.2.292","volume":"40","author":"AK Patick","year":"1996","unstructured":"Patick, A.K. et al. Antiviral and resistance studies of AG 1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40, 292\u2013297 (1996).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnm0796760_CR16","unstructured":"Schapiro, J.M. et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. (in the press)."},{"key":"BFnm0796760_CR17","volume-title":"Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency","author":"M Heath-Chiozzi","year":"1996","unstructured":"Heath-Chiozzi, M. et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan. 28\u2013Feb. 1, 1996, Abstract LB6b."},{"key":"BFnm0796760_CR18","volume-title":"Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine","author":"R Gulick","year":"1996","unstructured":"Gulick, R. et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan. 28\u2013Feb. 1, 1996, Abstract LB7."},{"key":"BFnm0796760_CR19","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","volume":"271","author":"AS Perelson","year":"1996","unstructured":"Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582\u20131586 (1996).","journal-title":"Science"},{"key":"BFnm0796760_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1126\/science.7824947","volume":"267","author":"JM Coffin","year":"1995","unstructured":"Coffin, J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483\u2013489 (1995).","journal-title":"Science"},{"key":"BFnm0796760_CR21","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1128\/JVI.68.3.2016-2020.1994","volume":"68","author":"DD Ho","year":"1994","unstructured":"Ho, D.D. et al. Characterization of HIV-1 variants with increased resistance to a C 2 symmetric protease inhibitor. J. Virol. 68, 2016\u20132020 (1994).","journal-title":"J. Virol."},{"key":"BFnm0796760_CR22","doi-asserted-by":"publisher","first-page":"9282","DOI":"10.1021\/bi00029a002","volume":"34","author":"SV Gulnik","year":"1995","unstructured":"Gulnik, S.V. et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34, 9282\u20139287 (1995).","journal-title":"Biochemistry"},{"key":"BFnm0796760_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0042-6822(95)80069-7","volume":"206","author":"H Jacobsen","year":"1995","unstructured":"Jacobsen, H. et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206, 527\u2013534 (1995).","journal-title":"Virology"},{"key":"BFnm0796760_CR24","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S0140-6736(95)90699-1","volume":"345","author":"VS Kitchen","year":"1995","unstructured":"Kitchen, V.S. et al. Safety and activity of saquinavir in HIV infection. Lancet 345, 952\u2013955 (1995).","journal-title":"Lancet"},{"key":"BFnm0796760_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1128\/AAC.37.5.1095","volume":"37","author":"AJ Japour","year":"1993","unstructured":"Japour, A.J., et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37, 1095\u20131101 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnm0796760_CR26","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1128\/JVI.69.9.5431-5436.1995","volume":"69","author":"B Maschera","year":"1995","unstructured":"Maschera, B., Furfine, E. & Blair, E.D. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69 5431\u20135436 (1995).","journal-title":"J. Virol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm0796-760","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm0796-760.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm0796-760.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:25:56Z","timestamp":1684452356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm0796-760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1996,7]]}},"alternative-id":["BFnm0796760"],"URL":"https:\/\/doi.org\/10.1038\/nm0796-760","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,7]]}}}